The Effect of Anesthesia on Neurodevelopmental Outcome (NDO) (NDO)
Anesthesia; Adverse Effect, Congenital Heart Disease, Neurodevelopmental Disorders
About this trial
This is an interventional prevention trial for Anesthesia; Adverse Effect
Eligibility Criteria
Inclusion Criteria:
- Neonates of at least 32 weeks of gestation, infants and children up to 2 years of age admitted to The Children's Hospital for treatment of cyanotic or non-cyanotic heart disease requiring surgical intervention.
- Admitting diagnosis of cyanotic or non-cyanotic heart disease
Exclusion Criteria:
- Neonates less than 32 weeks of gestational age, and children more than 2 years of age.
- Any documented central nervous system malformations.
- Any potential subject requiring unexpected postoperative Extracorporeal membrane oxygenation (ECMO) support
Sites / Locations
- Stanford Childrens hospital
Arms of the Study
Arm 1
Arm 2
Active Comparator
Active Comparator
Volatile Anesthesia
Narcotic based anesthesia
In volatile anesthetic technique, maintenance of anesthesia will be standardized to the anesthesia will be standardized to the volatile anesthetic isoflurane. Rocuronium or pancuronium will be used for muscle relaxation. Additionally, narcotic fentanyl will be administered at no greater than 2 mcg/kg/hr (low dose). However, the primary anesthetic during CPB will be isoflurane with no narcotic administered during CPB.
In narcotic based anesthetic technique, no volatile anesthetics will be used past induction. Maintenance of anesthesia will be with fentanyl 5 mcg/kg/hr not to exceed 10 mcg/kg/hr (high dose).